admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Small Pharma Announces SPL028 R&D Strategy Update

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Into the Psychedelic Practitioner Toolbox: Using a Transpersonal Approach

PT420 – DanceSafe: Drug Testing, Fentanyl Myths, and the Importance of...

Psychedelic Summer Safety: The Ultimate Guide to Making the Most Out...

Psychedelics Weekly – A Recap of Psychedelic Science 2023

Psychedelic Bulletin #140: Regulators Weigh in on Psychedelics; Psychedelic Biotech Strikes...

FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC.

Numinus to Host Q3 2023 Results Conference Call on July 17,...

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial...

1...585960...218 Page 59 of 218

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin